Jade Biosciences, Inc.
General ticker "JBIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $946.1M (TTM average)
Jade Biosciences, Inc. follows the US Stock Market performance with the rate: 49.0%.
Estimated limits based on current volatility of 3.9%: low 16.76$, high 18.12$
Factors to consider:
- Total employees count: 55 (+1275.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Inability to raise capital, No approved products, Regulatory and compliance, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.25$, 22.56$]
- 2026-12-31 to 2027-12-31 estimated range: [4.56$, 16.84$]
Financial Metrics affecting the JBIO estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 95.06 > 81.92
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -48.62 <= -40.59
Short-term JBIO quotes
Long-term JBIO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $81.41MM | $74.60MM | $113.54MM |
| Operating Income | $-81.41MM | $-74.60MM | $-113.54MM |
| Non-Operating Income | $5.94MM | $5.02MM | $-13.81MM |
| R&D Expense | $64.22MM | $53.19MM | $93.12MM |
| Income(Loss) | $-75.47MM | $-69.57MM | $-127.35MM |
| Taxes | $0.06MM | $0.06MM | $0.06MM |
| Net Income(Loss)* | $-75.52MM | $-69.63MM | $-127.41MM |
| Stockholders Equity | $109.46MM | $76.43MM | $332.52MM |
| Assets | $127.42MM | $80.33MM | $349.78MM |
| Operating Cash Flow | $-56.78MM | $-71.20MM | $-94.69MM |
| Capital expenditure | $0.14MM | $0.00MM | $0.20MM |
| Investing Cash Flow | $11.88MM | $56.03MM | $-247.03MM |
| Financing Cash Flow | $46.00MM | $25.43MM | $360.77MM |
| Earnings Per Share** | $-100.38 | $-85.26 | $-4.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.